Innate Pharma (IPHA) Liabilities and Shareholders Equity (2017 - 2025)

Innate Pharma (IPHA) has 9 years of Liabilities and Shareholders Equity data on file, last reported at $73.0 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity fell 38.48% year-over-year to $73.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $460.0 million (down 33.04% YoY) and the FY2025 annual result came in at $73.0 million, down 38.48% from the prior year.
• Liabilities and Shareholders Equity fell to $73.0 million in Q4 2025, from $105.2 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $320.6 million in Q2 2021 to a low of $73.0 million in Q4 2025.
• A 5-year average of $199.4 million and a median of $195.9 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity sank 99.9% — and 2022, when it declined 6.66%.
• Tracing IPHA's Liabilities and Shareholders Equity over 5 years: stood at $306.0 million in 2021, then plunged by 33.55% to $203.3 million in 2022, then fell by 7.3% to $188.5 million in 2023, then sank by 37.04% to $118.7 million in 2024, then slumped by 38.48% to $73.0 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $73.0 million (Q4 2025), $105.2 million (Q2 2025), and $118.7 million (Q4 2024), per Business Quant data.